AIRESS is a portable, autonomous, easy-to-use, and economical medical device class IIb (Europe) to replace mouth-to-mouth resuscitation techniques, which are absolutely advised against by COVID-19. This medical device will remain very useful and necessary in the post-pandemic era because it improves cardiorespiratory resuscitation procedures. Using AIRESS, a unique rescuer can attend to a patient by focusing on providing cardiac massage to the patient. AIRESS has an amazing market because is the right complement to a defibrillator (DEA). 300 units per 100K inhabitants is the ratio of DEAS deployed, for example, in Japan and US Help us to save lives by improving cardiorespiratory resuscitation techniques forever.

1. page
1
Airess
Emergency Resuscitator
Your Logo
Here
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era
Executive summary for investors

2. page
page
01. Elevator Pitch
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 2
✓ Chance of survival from a cardiac arrest is only 5%.
✓ Each minute decrease a 10% the option of survival
✓ Improve the results of Cardiopulmonary resuscitation (CPR) is a must.
✓ The American Hearth Association (www.heart.org) 2020 reports diagnose worldwide an
increase in mortality from cardiorespiratory arrest, this increase is associated with the null
application of Mouth to Mouth in the first instance in COVID times.
✓ TBIOM has developed AIRESS a portable, autonomous, easy to use, and economical
ventilator, medical device class IIb, to replace mouth-to-mouth resuscitation techniques.
2

3. page
page
02. The Challenge
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 3 3
03
01 02
Cardiopulmonary Resuscitation (CPR) improvement

4. page
page
03. Our solution - How it works
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 4 4
Video AIRESS operation (1 min 30 sec)
https://youtu.be/UHDu06nMQ-w

5. page
page
04. Cardiopulmonary Resuscitation (CPR) improvement
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 5 5
“Two randomized, controlled swine investigations using models of bystander
CPR for asphyxia cardiac arrest establish the following:
a) that prompt initiation of bystander CPR is a crucially important
intervention
b) b) that chest compressions plus mouth-to-mouth (ventilation) rescue
breathing is markedly superior to either technique alone. ”
https://journals.lww.com/ccmjournal/Abstract/2000/11001/Role_of_mouth_to_mouth_rescue_breathing_in.5.aspx
There is a coincidence between organizations and international scientific
institutions related to cardiac arrest such as:(ERC), (AHA), (ILCOR), US
“Institute of Medicine”, “Resuscitation Academy”, and the “Global
Resuscitation Alliance” in relation to the fact that cardiac arrest (CP) is a
problem of the first magnitude for public health and that there is a wide
margin to improve survival….
https://www.cercp.org/noticias/noticias-del-cercp/683-estrategia-parada-cardiaca

6. page
page
05. Challenge size - Market Opportunity
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 6 6
✓ AIRESS market is the same as AED Market
✓ AED market is growing 8% annually.
✓ The number of AED deployed will converge to Japan standard of
300 units per 100K inhabitants.
AIRESS complements Defibrillator (AED)
AIRESS provides autonomously air to the patient
8.65 B€
(300 units per 100K inhabitants)
2.79 B€
AED already deployed
AIRESS sale price 1300 €/unit
0,0
50,0
100,0
150,0
200,0
250,0
300,0
350,0
0,00
2.000,00
4.000,00
6.000,00
8.000,00
10.000,00
12.000,00
14.000,00
16.000,00
Spain Key european
countries Italy,
France,
Germany
Rest Europe China USA & Japan
Population 100K AED per 100K

7. page
page
06. Locations where AIRESS will be deployed.
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 7 7
Train Station
Beaches
Dental Clinics
Pools /Gym
Airports & planes.
Military
Naval
Non-Medical
ambulances
Emergency
services: Police
patrols, fireman
Nursing homes
Schools and
universities
300 units per 100K inhabitants.
Areas that are heavily concentrated with people at a given moment
Headquarters
Big buildings
Factories

8. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 8 8
07. Competitive Landscape (I)
Less complexity
More complexity
Less resources
More resources
MEDICALIZATED
ENVIRONMENTS
USER FRIENDLY & ANY LOCATION
TRAINING REQUIRED

9. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 9 9
07. Competitive Landscape (II)
AIRESS AMBU
HUDSON
VENTWAY O_TWO HAMILTON WEINMANN VYGON
Nº of rescuers 1 2 1 1 1 1 1
Needs oxygen Optional Optional Optional Optional Optional YES YES
Needs Pressured Air NO NO NO YES NO YES NO
Trained operator LOW HIGH MEDIUM HIGH HIGH HIGH MEDIUM
Needs ambulance NO NO NO YES NO YES NO
Weight Very Light Very Light HEAVY HEAVY HEAVY HEAVY HEAVY
Autonomous
Vcc Air O2
YES YES YES NO NO NO NO
Price Low Very Low High High Very High Very High Low
Single Use NO NO NO NO NO NO YES
Digital IoT Version 2 NO NO NO YES NO NO

10. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 10 10
08. Competitive Advantage
Only 30’ are necessary to apply AIRESS to a patient.
The rescuer can focus on cardiac massage or in applying a defibrillator. Only one
rescuer can apply both techniques. Substitutes the operation of the mouth-to-mouth
avoiding contagions.
1st Advantage – Quick & Safe Response
AIRESS can be used by non-healthcare persons due to its simplicity, anyone can perform
the cardiopulmonary resuscitation maneuver efficiency. Two bottoms: Adult - Kids
2nd Advantage – Easy to Use
5th Advantage – Digital Connected (version 2)
4th Advantage – Autonomous - Light – Small – Portable.
3th Advantage – Cost Effective
AIRESS is a very cheap Emergency Ventilator. It has CPR and RESPIRATOR modalities to
assist the patient's ventilation.
No need for an air intake or oxygen. Maintains PEEP pressure without requiring a special
valve. Battery powered with a duration of more than 4 hours. It includes an anatomical
support to perform the forehead-chin maneuver and masks of two sizes.
Record and transmit main live parameters. We will build the biggest database about
ventilation during a cardiac arrest ever available. GPS localization.

11. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era
09. Patents – Intellectual Property (IP)
Number Description
WO/2020/070349 Drive device to provide assisted ventilation, comprising an air inlet, an
impeller provided with blades driven in rotation by a motor, and an air outlet,
causing the rotation of said impeller the circulation of air through a duct from
the air inlet to the air outlet, characterized in that said blades of the impeller
they are flexible, vibrating at least one of their ends by the thrust caused by
said circulating air
WO/2020/221952 A portable insufflator device for artificial ventilation intended to couple
operationally at the mouth of a patient
Exclusivity Right
201930714 ES Provides an acoustic silencer that minimizes space requirements and
materials, obtaining high sound attenuation and low pressure drop of the
fluid.
201530458 ES An air blowing device to provide assisted ventilation during spontaneous
breathing comprising a motor; a fan driven by the motor, and a casing
defining a housing for the fan, the housing being connectable through a
single inlet and outlet port to a respiratory mask adjustable to a patient, in
which a pressure within the housing is adjustable as a function of a rotational
speed of the ventilator such that, in use, an air flow of Inspiration and a flow
of expiratory air circulate substantially through the inlet and outlet port.
11

12. page
page
10. Business Model - B2B
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 12 12
Sell AIRESS through a worldwide
network of AED distributors
Out of Europe: transport no included. Maintenance service don’t include clean service after each use.
• Build a big portfolio
• Services included
• Virus filters and Disinfection Firmware/software upgrade.
• Reposition NBD.
• Spare pieces
• Hot line support
Concept Europe Out of Europe
Unit 1300 € 1300 €
Yearly upgrade quote 480 € 480 €
Yearly quote
Sell AIRESS units + yearly maintenance service
Option Renting: 36-60 monthly quote

13. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 13 13
11. Growth Strategy
The support of the patients and healthcare influencers will fuel the growth
of our solution
The Change comes from people
Tactical
Strategic
✓ Agreements with patient
associations.
✓ Agreements with universities and
collages
✓ Spain emergency services.
✓ Support of Spanish doctors and
hospitals: Can Ruti, Parc Tauli
Technology
✓ Industry events: congress,
conferences, trade shows
✓ Speaking opportunities
✓ Articles in Magazines and
Newspapers.
✓ Big presence in social networks
& blogs

14. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 14 14
Two sources of income: sales + maintenance contracts
Long Term Business
12. Business growth
0
10.000
20.000
30.000
40.000
50.000
60.000
70.000
2022 2023 2024 2025 2026 2027
Ud.
Year
Sales
Airess units sells Mainteinance contracts
Realistic approach
We need some time
to get a significant
market penetration
Building a portfolio
of maintenance
contracts
Sells will begin in 3Q 2022
Services ratios over sells
Ratio EU Out EU
Maintenance Ratio 85,00% 60,00%
Renovation Ratio 95,00% 80,00%

15. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 15 15
13. Financials
-10.000.000
0
10.000.000
20.000.000
30.000.000
40.000.000
50.000.000
60.000.000
70.000.000
80.000.000
90.000.000
2022 2023 2024 2025 2026 2027
€
Year
Income Operating cost EBITDA R&D Investments Cash Flow Net Benefits
2027 TURNOVER
76.3 M€
ENTERPRISE VALUE 2027
311.5 M€
152.6 M€
CONSERVATIVE VALUE OPTIMISTIC VALUE
2027 EBITDA
31.15 M€
% 41,38
2021-27
ACCUMULATED BENEFITS
35.17 M€
More info in annex A.

16. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 16 16
14. Fundraising strategy
2nd Round – Capital invested for international expansion
3rd Round – Capital invested to achieve the break even
INVESTMENT
2,0 M € x 28
SHARES RETURN 2027
INVESTMENT
x 12
SHARES RETURN 2027
1st Round – Capital invested to homologate AIRESS
INVESTMENT
10 %
€
x 45
SHARES RETURN 2027
8 %
20 %
0,5 M €
2,0 M €
Open process: fusion of rounds is possible

17. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 17 17
15. Funding Needs 2021-2027
4,5 M €
Development AIRESS version 2
Telemedicine – Big Data – GPS location – life parameters real-time remote
monitorization
CE Mark : 500 K€
Homologation AIRESS
CE Mark other ventilators prototypes
Marketing and promotion in Europe: Spain,
Germany, France, Italy
IP Protection & Patents
Improve AIRESS manufacturing process
General expenses, staff, advisors, administration &
fund raising
Airmony -CPAP - PPI
Get international patents: Europe, Usa, China
Substitute 3D printing by plastic injection

18. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 18 18
16. Timeline – 2022-2024
3Q 2022 – Ready to market in Europe
Step 1
2015-2020
3 ventilators
prototypes design
Step 2
AIRESS Prototype
Development
Finished
We are here
Step 3 2Q21
AIRESS
homologation
Step 5
AIRESS DIGITAL
App – portal – remote
control - GPS
Step 8
Launch operations in
Asia
Step 7
CE Mark Airmony & EPI
Ventilators
Step 4 3Q21
Commercial operations in
Spain, France, Germany,
Italy
Step 4
Prototype reengineering for
massive industrial
production
International vocation
Continuous investments in R&D

19. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 19 19
17. Our Team
JAUME PALOU
CTO, CEO & CO-Founder
Electronic Engineer
Master in Project Management
Executive Master Certified
Dr. MIQUEL SISTERÉ
Medical Director & CO-Founder
Bachelors in Medicine
FRANCESC MARTÍNEZ
Business Director & Co-Founder
Master in International
Commercial Trade and Legislation
Medical Advisors
Dr. AGUSTÍ RUIZ
Bachelors in Medicine
Master in emergency and
urgency medicine
Dr. ANTONI ROSELL
Bachelors in Medicine
Head of thoracic Medicine
Hospitals

20. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 20 20
18. Loaners & other investors
Crowdfunding
Spanish Government entities
Banks

21. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 21 21
19. Industrial partners
European partners & providers
3D printing
Motors
Electronic Manufacturing
Mechanical engineering
Distributors

22. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 22 22
20. Healthcare sector Project supporters
JUAN CARLOS RODRIGUEZ MELENDEZ
Emergency doctor.
Hospital Universitario San Juan
Alicante
JOSE JAVIER AROCA
Emergency technician
Grupo ASV
- Lourdes José Alcaide - Noelia García Aracil - Mercedes Herrero Davó - Juan González Torren - Barbara Muñoz
Amorós - David Nullor Gil - Rogelio Martínez - Salvador Esteve Martínez
- Francisco Barragian - Javier González Alasarín - Ignasi García Olivé - Beatriz Morales Lopez
Emergency doctors & technician
MANUEL LUJAN
Neumologist - Expert in ventilation
Hospital Parc Tauli – Sabadell - Barcelona
Video test: bit.ly/3tz2wjZ

23. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 23 23
21. Other developments (I)
I- Personal Protection Ventilator - PPV
CE Mark pendent
Status of the project
Autonomous and light ventilator for persons working in biological or
non-biological contaminated areas.
Provides filtered air free of virus and other particles for 4 h using
standard USB batteries.
Quite more comfortable and safer and much less tired than wearing
two masks, FFP2 and surgical, because the user is not forcing the
breath
Dr. Sistare has tested the device when serving
in Arnau de Vilanova Hospital in Lleida, Spain,
during the worst days of COVID pandemia

24. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 24 24
21. Other developments (II)
II- AIRMONY – Apnea CPAP
CE Mark pendent
Status of the project
Hoseless CPAP Ventilator (Continuous positive airway pressure),
portable, small, light, quiet, and autonomous, improve treatment
adherence, allowing distance control of the device and the patient’s
status.
Demo video: https://youtu.be/piM3CamAWrQ
Project web: www.yourairmony.com
Market size
936 Million of patients
Mature Market. Significant competitors

25. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 25 25
21. Other developments (III)
III- COPD, Chronic obstructive pulmonary
disease, diagnosis and monitoring using
oscilometry
Proof of concept
Developed in partnership with breaz www.breaz.eu
Status of the project
Oscilometry is a technology used to measure the impedance of the airways (resistance
and reactance). It has been clinically tested to measure the severity of obstructive
lung diseases, particularly lower respiratory diseases such as asthma and COPD. It has
been used primarily as a supplemental respiratory test, but the complexity of the
results, the relatively large size of the device, and high costs have limited its use in
highly specialized hospitals. Furthermore, it is specific to lower respiratory disease
and cannot distinguish or identify possible respiratory diseases such as obstructive
sleep apnea.
The project aims to develop a medical device for diagnosis and monitor respiratory
diseases using oscilometry technology. A key component of this new device is a CPAP
that allows to synchronize the device with patient’s breath obtaining a much better
and wide measurement.
Market size
936 Million of OSA patients
300 Million of COPD patients
Every hour around 350 people dies from COPD around the world

26. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 26 26
21. Other developments (IV)
IV- VNAP
Developing prototype in conjunction with Girona University www.udg.edu
Status of the project
Variable Negative Air Pressure is a new technology to treat obstructive
sleep apnea (OSA) patients.
The VNAP technology's objective is to strengthen the nose and mouth
cavity muscles and improve their opening at night during sleep, thus
reducing the number of apneas.
Market size
936 Million of patients
Disruptive new treatment.

27. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 27 27
21. Other developments (III)
V-Electronic Stethoscope
First prototype.
Proof of concept on going at Trias I Pujol Hospital (Badalona – Spain)
Status of the project
Electronic stethoscope connected to mobile for remote auscultation of
patients.
The signal would be recorded in the cloud.
Pattern recognition analysis will be available for automatic diagnosis
Market size
The global stethoscope market size was valued at USD 400.8
million in 2019 and is expected to grow at a compound annual
growth rate (CAGR) of 4.9% from 2020 to 2027
(grandviewresearch.com)

28. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 28 28
22. Why to invest?
1) Will save the life of millions of persons protecting the health
of the emergency teams
2) Improve Cardiorespiratory resuscitation techniques is a
must.
3) It’s a e-health and Healthcare Digital transformation
project.
4) It’s the right momentum for a quick adoption of AIRESS. It’s a
disruptive solution in the COVID era.
5) It’s a long-term good business, Excellent EBITDA 40%, great
portfolio of products and on-going services
TBIOM mission is to save human lives providing efficient
medical device for respiratory patients

29. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 29 29
21. Key Metrics – 2027 Objectives
TURNOVER
76.3 M€ 311 M€
88.1K
TURNOVER
MAINTEINANCE
AGREEMENTS’
PORTFOLIO
ENTERPRISE VALUE
TOTAL UNIT SOLD
64.97K

30. page 30
Contact Info
Your Logo
Here
Thank You
Don’t hesitate to contact us if you need further information.
Hope to see you on board
aac@argelich.com
@aargelich
+34 934151235 / +34 610595053
Agustin Argelich
www.linkedin.com/in/agustinargelich/
IMPROVIG CARDIORESPIRATORY RESUCITATION IN COVID-19 & POST COVID ERA
WWW www.argelich.com

31. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 31 31
Disclaimer
This document has been prepared by Argelich Network Management Services S.L. (ANMS) for the exclusive use of the person o legal entity to which it is delivered
(INVESTOR). As INVESTOR must be understood also their collaborators, employees and advisers, whether they are internal or external to their organization and their
subsidiaries. Contains sensitive, confidential and privileged information. The information contained therein is property of ANMS and/or the current owners of the Company, or of
the intellectual propriety rights, or of the assets that are presented.
Distribution of this presentation to third parties is strictly prohibited. The persons to whom it is allowed to distribute must be informed of the distribution restrictions and the
confidentiality of the present document.
The documentation has been produced for the sole purpose of illustrating and facilitating the discussion of a potential agreement between INVERSOR and owners. The
valuations, forecasts, estimates, opinions and projections contained in this document involve subjective judgment and analysis. ANMS has collected, received, compiled and
processed public and private information (whenever possible its source is mentioned), but has not verified and there is no guarantee in any case about its completeness,
reliability or accuracy. There is no implicit or explicit commitment on the part of ANMS. This presentation may contain forward-looking statements. ANMS does not contract an
obligation to update based on future events or changes in any circumstances. Any information or opinion is subject to change without notice. There is no guarantee that the
projections included in the presentation will be met. Actual results may vary substantially from projections. ANMS, its directors, employees, partners, employees and agents
explicitly reject any responsibility related to or derived from the total or partial use of this presentation.
This document has been prepared exclusively for information and should not be construed as an application to buy or sell securities, intellectual property rights, materials, asset,
or financial instruments. The INVESTOR should never interpret the contents of this document as an advice or a tax, legal or financial recommendation. The INVESTOR must
consult with its own legal, tax and financial advisors before making any decision related to any proposed transaction, described or derivative from the present document. This
presentation does not have to include all the information that the INVESTOR may require. Moreover, there is no investment or divestment decision that can be taken based
solely on the information included in this presentation

32. page
page
A. Challenge size - Market Opportunity data
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 32 32
Population 100K AED per 100K AED deployed
Potential market 300
units per 100K
inhabitants
Spain 469,40 40,4 18.956 140.820
Key European countries Italy, France,
Germany 1.356,52 169,7 230.143 406.956
Rest Europe 1.826,80 215,3 393.351 548.040
China 13.930,00 10,0 139.300 4.179.000
USA & Japan 4.547,00 300,0 1.364.100 1.364.100
Total target Market 2.145.850 6.638.916

33. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 33
B. Financial Projections – Summary
Sales 2022 2023 2024 2025 2026 2027
Units sold 500 2.498 7.068 11.232 26.571 40.242
Average Price € 1.300 1.300 1.300 1.300 1.300 1.300
Units Sold € 650.000 3.247.724 9.188.120 14.601.030 34.541.910 52.314.478
Mainteinance contracts 425 2.527 8.409 17.399 36.517 64.972
Average Price € 480 480 480 480 480 480
Services sold 51.000 703.443 2.594.259 6.092.792 12.730.966 23.919.226
Total Sales € 701.905 3.954.174 11.791.268 20.711.701 47.309.873 76.299.156
Total regular cost 1.681.644 4.500.056 9.306.827 14.767.920 29.334.707 45.148.530
EBITDA -979.739 -545.883 2.484.441 5.943.781 17.975.166 31.150.626
Margin(%) -13,81% 21,07% 28,70% 37,99% 40,83%
R&D Investments 1.069.020 1.191.312 1.717.197 2.211.667 3.161.704 4.129.856

34. page
page
Airess Emergency Resuscitator – Improving Cardiorespiratory techniques in the Covid and post Covid era 34
C. Data sheet – Summary